Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
💡 한 문장 핵심
폐경전 여성의 다모증 평가 및 치료: Endocrine Society 임상진료지침.
가이드라인
4/5 보강
TL;DR
This evidence-based guideline recommends testing for elevated androgen levels in all women with an abnormal hirsutism score and recommends against antiandrogen monotherapy unless adequate contraception is used and against using insulin-lowering drugs.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.
📑 코퍼스 인용 관계
· 인용됨 21
📑 인용한 논문 (6) ▾
- Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation… American journal of clinical dermatology · 2026
- Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen f… EClinicalMedicine · 2025
- Follicular Unit Excision Hair Removal of Unwanted Facial Terminal Hair in Five Facial Area… Aesthetic plastic surgery · 2025
- Normative Data for Modified Ferriman-Gallwey Score and the Prevalence of Hirsutism in Youn… Indian journal of endocrinology and metabolism · 2024
- Comparison of self-assessed and clinician-assessed hirsutism diagnosed according to the mo… Archives of endocrinology and metabolism · 2024
- Efficacy of topical minoxidil in enhancing beard growth in a group of transgender assigned… Journal of endocrinological investigation · 2024
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
폐경 전 여성의 다모증(hirsutism) 평가 및 치료에 관한 내분비학회(Endocrine Society) 임상진료지침의 2008년판을 최신 근거에 맞게 개정하기 위한 연구입니다.
【방법】
의학 전문가 7인과 방법론 전문가로 구성된 학회 태스크포스가 GRADE 시스템을 적용해 권고 강도와 근거 수준을 평가하였으며, 2건의 체계적 문헌고찰을 새로 의뢰하고 기존 체계적 고찰 및 개별 연구의 최선 근거를 종합하였습니다.
【주요 결과】
다모증 점수(hirsutism score)가 비정상인 모든 여성에게는 안드로겐 수치 검사를 권고하나, 점수가 정상인 국소 원치 않는 털 성장에는 검사를 권고하지 않습니다. 약물치료는 대부분 경구 복합 에스트로겐-프로게스틴 피임제(combined oral contraceptive)로 시작하고 6개월 후 반응이 미흡하면 항안드로겐제(antiandrogen)를 추가하며, 피임 없는 항안드로겐 단독요법과 인슐린 저하제(insulin-lowering drug) 사용은 권고하지 않습니다. 직접 제모는 레이저/광제모(laser/photoepilation)를 우선 권고합니다.
【임상적 시사점 (성형외과 의사 관점)】
미용 목적으로 제모를 원하는 환자에게는 레이저/광제모가 1차 권고이므로 적극 활용할 수 있으나, 다모증 점수가 비정상인 환자는 시술 전 내분비 이상(특히 PCOS) 감별을 위해 안드로겐 검사 및 내분비 의뢰를 고려해야 합니다. 중등도 이상 다모증에서는 제모 단독보다 약물치료 병행이 재발 억제에 유리하므로, 미용 시술과 호르몬 치료의 협진 모델을 안내하는 것이 효과적입니다.
[OBJECTIVE] To update the "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline," published by the Endocrine Society in 2008.
[PARTICIPANTS] The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist.
[EVIDENCE] This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies.
[CONSENSUS PROCESS] Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines.
[CONCLUSION] We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.
[PARTICIPANTS] The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist.
[EVIDENCE] This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies.
[CONSENSUS PROCESS] Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines.
[CONCLUSION] We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.
【연구 목적】 폐경 전 여성의 다모증(hirsutism) 평가 및 치료에 관한 내분비학회(Endocrine Society) 임상진료지침의 2008년판을 최신 근거에 맞게 개정하기 위한 연구입니다.
APA 7
Martin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018). Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline.. The Journal of clinical endocrinology and metabolism, 103(4), 1233-1257. https://doi.org/10.1210/jc.2018-00241
Vancouver
Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Jour. clin. endo. meta.. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241
AMA 11
Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Jour. clin. endo. meta.. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241
Chicago
Martin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., and Rosenfield, R. L.. 2018. "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline." The Journal of clinical endocrinology and metabolism 103 (4): 1233-1257. https://doi.org/10.1210/jc.2018-00241
MLA 9
Martin, K. A., et al. "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline." The Journal of clinical endocrinology and metabolism, vol. 103, no. 4, 2018, pp. 1233-1257. doi:10.1210/jc.2018-00241.
PMID
29522147 ↗
추출된 의학 개체 (NER)
상태/진단
다모증 hirsutism
×6
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | hirsutism
|
다모증 | dict | 6 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🤖 이 논문을 인용한 AI 인사이트 · 2건
📰 주간
다모증 핵심은 PCOS·안드로겐 평가
P: 다모증(hirsutism) 환자, 특히 다낭성난소증후군(PCOS) 동반 여성 및 비-PCOS 다모증 집단, PCOS 임신부와 그 자녀를 포함. O: 유병률, 표현형 분류, 안드로겐·인슐린 저항성 등 대사 지표 기여도, 다모증 객관적 정량화(영상 기반 모발 평가), PCOS 임신 합병증과 자녀
📰 주간
다모증 핵심 원인은 PCOS
P: 안드로겐 과다 표현형을 동반한 다모증 환자, 특히 다낭성난소증후군(PCOS) 여성. Rotterdam, NIH, AES 등 진단 기준에 따라 정 O: 다모증을 PCOS의 표현형으로 통합 해석하는 진단적 분류와 유병률(진단 기준 간 5–10% 차이). 표준화된 측정 도구, 장기 임신·대사 결과,
이 논문은 위 AI 빅데이터 분석에 인용된 근거 논문입니다.
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Hormonal Effects on Hair Follicles.
- Prevalence of Hirsutism Among Reproductive-Aged African American Women.
- Menstrual patterns and self-reported hirsutism as assessed via the modified Ferriman-Gallwey scale: …
- Evaluation and Treatment of Hirsutism in Premenopausal Women.
- Ovarian Leydig cell tumor and postmenopausal hirsutism with signs of virilisation.
- Efficacy of topical minoxidil in enhancing beard growth in a group of transgender assigned female at…
- Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospe…
- Comparison of image-based modified Ferriman-Gallway score evaluation with in-person evaluation: an a…
- Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in …
- Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Trea…
- Follicular Unit Excision Hair Removal of Unwanted Facial Terminal Hair in Five Facial Areas: A Retro…
- Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycys…
- Comparison of self-assessed and clinician-assessed hirsutism diagnosed according to the modified Fer…
- Normative Data for Modified Ferriman-Gallwey Score and the Prevalence of Hirsutism in Young South In…
- Assessment of Health-Related Quality of Life in Patients with Idiopathic Hirsutism Compared to Patie…
- Non-PCOS Hyperandrogenic Disorders in Adolescents.
- SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirs…
- The prevalence of heterozygous CYP21A2 deficiency in patients with idiopathic acne, hirsutism, or bo…
- Female Androgenetic Alopecia with Male Pattern Caused by an Androgen-Producing Tumor.
- Adrenocortical carcinoma: an ominous cause of hirsutism.
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 미국 임상내분비학회, 미국 내분비학회, 안드로겐 과다 및 PCOS 학회 질환 임상 리뷰: 다낭성 난소 증후군의 평가와 치료를 위한 최선의 진료 지침--1부.
- 임상 진료. 다낭성 난소 증후군.
- 외인성 testosterone(T) 단독 또는 finasteride 병용 투여는 혈청 T가 낮은 고령 남성에서 신체 수행 능력, 악력 및 제지방량을 증가시킨다.
- 이중 5alpha-reductase 억제제인 dutasteride에 의한 양성전립선비대증 남성에서의 dihydrotestosterone의 현저한 억제.
- PCOS의 유전적, 호르몬적, 대사적 측면: 최신 동향.
- 다모증 치료에서 spironolactone, flutamide, finasteride의 효능 비교: 무작위 이중맹검 위약대조 시험.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Review of Hair Follicle Dermal Papilla cells as in vitro screening model for hair growth.
TL;DRThe pivotal role of DPCs in the forefront of hair research as screening platforms is highlighted by providing insights into mechanistic action at cellular level, which may further …
-
Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey.
TL;DRThe rate of androgenetic alopecia was found to be higher than the other studies made in Asian and Caucasian populations, and correlation with age in both genders was correlated wit…
-
Female pattern hair loss.
TL;DRThis review addresses the clinical presentation of female pattern hair loss, its differential diagnosis and treatment modalities, and describes off-label alternative modalities of …
-
Hair disorders in patients with cancer.
TL;DRClinical significant therapy-related hair disorders in oncology patients are reviewed, including the underlying pathophysiological mechanisms, severity grading scales, patient-repo…
-
Hair disorders in cancer survivors.
TL;DRThe information contained in this continuing medical education series should facilitate a better understanding on hair disorders in cancer survivors so that adequate support and th…